Improvement of nutritional condition of the patients with inoperable pancreatic cancer by Kestose

Improvement of nutritional condition of the patients with inoperable pancreatic cancer by Kestose - Treatment with Kestose for inoperable pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027256

Enrollment

Registered

2017-05-24

Start date

2017-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inoperable pancreatic cancer

Interventions

Kestose placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as inoperable pancreatic cancer

Exclusion criteria

Exclusion criteria: 1.Women with pregnancy or possible pregnancy 2.Patients with severe renal failure and heart failure 3.Patient who is considered to be inappropriate for entry into the trial by the investigator 4.Patients with substantial alcohol consumption(20g/day for women or >30g/day for men 5.Patient who is poor in ingestion 6.Patient with other pancreas disease or other cancer 7.Patient who receive other treatments such as chemotherapy,radiotherapy and operation 8.Patients who take nonabsorbable antibiotics

Design outcomes

Primary

Measure	Time frame
Improvement of nutritional condition in the patients with inoperable pancreatic cancer	—

Secondary

Measure	Time frame
1.Changes of Performance status(KPS) 2.Changes of The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire(EURTC-QLQ-C30) 3.Changes of total energy expenditure(TEE) 4.Changes of short-chain fatty acid(Butyric acid,Acetic acid,Prorionic acid etc.) 5.Changes of Rapid turnover protein 6.Correlation of gut microbiota and therapeutic effect 7.Metabolome,bile acid and protein analysis of metabolite in feces 8.Correlation between expiratory noble gases,gut microbiota and pancreatic cancer 9.Successful execution rate of Chemotherapy 10.Frequency and degree of side effect 11.Prognosis of inoperable pancreatic cancer	—

Measure

Time frame

1.Changes of Performance status(KPS) 2.Changes of The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire(EURTC-QLQ-C30) 3.Changes of total energy expenditure(TEE) 4.Changes of short-chain fatty acid(Butyric acid,Acetic acid,Prorionic acid etc.) 5.Changes of Rapid turnover protein 6.Correlation of gut microbiota and therapeutic effect 7.Metabolome,bile acid and protein analysis of metabolite in feces 8.Correlation between expiratory noble gases,gut microbiota and pancreatic cancer 9.Successful execution rate of Chemotherapy 10.Frequency and degree of side effect 11.Prognosis of inoperable pancreatic cancer

—

Countries

Japan

Contacts

Public ContactDaisuke Sakai

Nagoya University Hospital Department of Gastroenterology and Hepatology

sakai@med.nagoya-u.ac.jp+81-52-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026